CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
Pneumobase.it

Search results for "Stable coronary artery disease"

New study has showed that antibiotic treatment does not reduce risk of secondary cardiac events. . Taking antibiotics weekly for one year does not reduce the risk of a heart attack or other cardiac e ...


FDA ( Food and Drug Administration ) has approved Aceon ( Perindopril erbumine ) tablets for the treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortalit ...


Percutaneous coronary intervention ( PCI ) plus optimal medical therapy does not improve outcomes in patients with coronary artery disease, compared with optimal medical therapy alone. The Clinical ...


A randomised multicentre open-label study was evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy ...


Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation permanent polymer drug-eluting stents.The aim of a study was to inve ...


It has been investigated whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. A large number of trials compared the diffe ...


It was hypothesized that in patients with stable coronary artery disease and stenosis, percutaneous coronary intervention ( PCI ) performed on the basis of the fractional flow reserve ( FFR ) would be ...


Treatment of hypertensive patients with beta-blockers reduces heart rate and decreases central blood pressure less than other antihypertensive drugs, implying that reducing heart rate without altering ...


At the European Society of Cardiology Congress 2019, researchers from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris, have presented the results from T ...


Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting. The results ...


The combination of Ticagrelor ( Brilique ) and Aspirin ( Acetylsalicylic acid ) reduces ischaemic events compared with Aspirin alone in patients with stable coronary artery disease and diabetes. The ...